Archemix sells hemophilia drug assets to Baxter for up to $305M

Mon, 11/22/2010 - 5:37am
Mass High Tech: The Journal of New England Technology

Cambridge-based Archemix Corp. has agreed to sell all of its hemophilia-related assets to Illinois life sciences company Baxter International Inc. for a deal that could be worth up to $305 million for Archemix.

The deal, which also includes an exclusive license agreement for certain hemophilia-related intellectual property assets from Archemix, will have Baxter (NYSE: BAX) paying $30 million in an upfront fee for the assets. Baxter may also make milestone payments to Archemix of up to $285 million. The deal is expected to close by the end of the year, subject to the usual conditions.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.